| Recombinant anti-human HER2/neu IgG3-(GM-CSF) fusion protein retains antigen specificity and cytokine function and demonstrates antitumor activity JS Dela Cruz, KR Trinh, SL Morrison, ML Penichet The Journal of Immunology 165 (9), 5112-5121, 2000 | 106 | 2000 |
| An anti-transferrin receptor-avidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells PP Ng, JS Dela Cruz, DN Sorour, JM Stinebaugh, SU Shin, DS Shin, ... Proceedings of the National Academy of Sciences 99 (16), 10706-10711, 2002 | 102 | 2002 |
| Protein vaccination with the HER2/neu extracellular domain plus anti-HER2/neu antibody–cytokine fusion proteins induces a protective anti-HER2/neu immune response in mice JS Dela Cruz, SY Lau, EM Ramirez, C De Giovanni, G Forni, SL Morrison, ... Vaccine 21 (13-14), 1317-1326, 2003 | 92 | 2003 |
| Antibody-cytokine fusion proteins: innovative weapons in the war against cancer JS Dela Cruz, TH Huang, ML Penichet, SL Morrison Clinical and experimental medicine 4 (2), 57-64, 2004 | 76 | 2004 |
| A recombinant IgG3-(IL-2) fusion protein for the treatment of human HER2/neu expressing tumors ML Penichet, JS Dela Cruz, SU Shin, SL Morrison Human antibodies 10 (1), 43-49, 2001 | 67 | 2001 |
| Vaccination with novel combinations of anti-HER2/neu cytokines fusion proteins and soluble protein antigen elicits a protective immune response against HER2/neu expressing tumors G Helguera, JS Dela Cruz, C Lowe, PP Ng, R Trinh, SL Morrison, ... Vaccine 24 (3), 304-316, 2006 | 40 | 2006 |
| Insights into the mechanism of anti-tumor immunity in mice vaccinated with the human HER2/neu extracellular domain plus anti-HER2/neu IgG3-(IL-2) or anti-HER2/neu IgG3-(GM-CSF … JS Dela Cruz, SL Morrison, ML Penichet Vaccine 23 (39), 4793-4803, 2005 | 35 | 2005 |
| Antibody fusion proteins: effective adjuvants of protein vaccination ML Penichet, JS Dela Cruz, L Peng, SL Morrison US Patent 7,736,652, 2010 | 31 | 2010 |
| Mechanism of antitumor activity of a single-chain interleukin-12 IgG3 antibody fusion protein (mscIL-12. her2. IgG3) LS Peng, ML Penichet, JS Dela Cruz, SL Sampogna, SL Morrison Journal of Interferon & Cytokine Research 21 (9), 709-720, 2001 | 31 | 2001 |
| Anti-HER2/neu IgG3–(IL-2) and anti-HER2/neu IgG3–(GM-CSF) promote HER2/neu processing and presentation by dendritic cells: Implications in immunotherapy and vaccination strategies JS Dela Cruz, KR Trinh, HW Chen, A Ribas, SL Morrison, ML Penichet Molecular immunology 43 (6), 667-676, 2006 | 27 | 2006 |
| A murine B cell lymphoma expressing human HER2/neu undergoes spontaneous tumor regression and elicits antitumor immunity ML Penichet, JS Dela Cruz, PM Challita-Eid, JD Rosenblatt, SL Morrison Cancer Immunology, Immunotherapy 49 (12), 649-662, 2001 | 9 | 2001 |
| Protein M fusion proteins and uses J Dela Cruz https://patents.google.com/patent/US11401309B2/en, 2022 | | 2022 |
| New insights underlying the early events of dopaminergic dysfunction in Parkinson’s Disease HL Dela Cruz, EL Dela Cruz, CJ Zurhellen, HT York, JA Baun, ... bioRxiv, 2020.09. 27.313957, 2020 | | 2020 |
| TREATMENT OF SYNUCLEINOPATHY AND ANIMAL MODELS OF SYNUCLEINOPATHY JS Dela Cruz https://patents.google.com/patent/US20220135968A1/en, 2019 | | 2019 |
| Development of PKC Theta-Specific Inhibitors to Modulate T-Cell Activation (B35) F Karim, A Baruch, J Dela Cruz, D Maclean, K Das, S Harrision The Journal of Immunology 178 (1 Supplement), LB7-LB7, 2007 | | 2007 |
| Mechanism of apoptosis induced by an IgG3-avidin fusion protein specific for the human transferrin receptor PP Ng, SZ Lomas, JS Dela Cruz, G Helguera, B Bonavida, SL Morrison, ... Cancer Research 65 (9 Supplement), 531-531, 2005 | | 2005 |
| Combinations of cytokines fused to antibodies to enhance the immune response against HER2/neu expressing tumors GF Helguera, JS Dela Cruz, C Lowe, PP Ng, R Trinh, SL Morrison, ... Cancer Research 65 (9 Supplement), 166-167, 2005 | | 2005 |
| Characterization of two bi-functional anti-HER2/neu IgG3-cytokine fusion proteins with potential use as cancer therapeutics GF Helguera, VR Kyinn, C Lowe, JS Dela Cruz, R Trinh, PP Ng, ... Cancer Research 64 (7 Supplement), 1078-1078, 2004 | | 2004 |
| Anti-HER2/neu IgG3-(IL-2) efficiently redirects HER2/neu antigen processing in dendritic cells resulting in effective antigen presentation and tumor protection. JS Dela Cruz, HW Chen, RK Trinh, S Narasimhan, WP Naing, A Ribas, ... Cancer Research 64 (7 Supplement), 495-496, 2004 | | 2004 |
| Anti-HER2/neu IgG3-(IL-2) and anti-HER2/neu IgG3-(GM-CSF) antibody fusion proteins are potent adjuvants of HER2/neu vaccination: Characterization of a HER2/neu specific anti … JS Dela Cruz University of California, Los Angeles, 2004 | | 2004 |
